Drugs / Androxal
Androxal
Trials 25
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT02274181 | Dec 2014 → Jan 2015 | hypogonadism | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02169804 | Aug 2014 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02146391 | Jun → Jul 2014 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01991327 | May → Jul 2014 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02117830 | Apr → May 2014 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01984398 | Dec 2013 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01959685 | Oct → Nov 2013 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01923870 | Aug 2013 → Jan 2014 | hypogonadism | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01923857 | Aug 2013 → Aug 2014 | hypogonadism | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT02651688 | Jan 2016 → May 2017 | hypogonadotropic hypogonadism, obesity disorder | Repros Therapeutics Inc. | Completed | Mixed |
| Phase 2 | NCT01386567 | Jul 2011 → Jan 2013 | hypogonadism, male | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01386606 | Jun → Oct 2011 | hypogonadotropic hypogonadism | Repros Therapeutics Inc. | Completed | Missed primary |
| Phase 2 | NCT01270841 | Jan → Dec 2011 | hypogonadotropic hypogonadism | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01191320 | Oct 2010 → Dec 2011 | hypogonadism, type 2 diabetes mellitus | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00706719 | Jun 2008 → Jul 2009 | hypogonadotropic hypogonadism | Repros Therapeutics Inc. | Completed | Mixed |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02160704 | Sep 2014 → Aug 2016 | male infertility | Baylor College of Medicine | Withdrawn | No outcome recorded Stop: Business |
| Phase 39 trials | ||||||
| Phase 3 | NCT01993225 | Jan → Aug 2014 | hypogonadotropic hypogonadism | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01993212 | Jan → Sep 2014 | hypogonadotropic hypogonadism | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01739595 | Nov 2012 → Sep 2013 | hypogonadotropic hypogonadism | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01739582 | Nov 2012 → Apr 2014 | hypogonadotropic hypogonadism | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01619683 | Sep 2012 → Sep 2014 | — | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01532414 | Aug 2012 → Mar 2013 | hypogonadotropic hypogonadism | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01534208 | May 2012 → Oct 2013 | hypogonadotropic hypogonadism | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00962637 | Mar 2006 → May 2007 | hypogonadotropic hypogonadism | Repros Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01067365 | Mar 2006 → May 2007 | hypogonadism | Repros Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Androxal | “Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily” NCT01739595 ↗ |
| Known as | enclomiphene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01619683 ↗ |
| Known as | enclomiphene citrate | “Enclomiphene citrate capsules 25 mg 1x daily for 16 weeks” NCT02160704 ↗ |
| Known as | trans-clomiphene | “Enclomiphene (trans-clomiphene) citrate (Androxal) was evaluated to determine if Androxal increased serum testosterone levels in men with secondary hypogonadism.” NCT00962637 ↗ |
| Route | Oral | “25 mg Androxal capsules, 1 capsule daily for 6 months” NCT00706719 ↗ |